The pathology of primary pulmonary hypertension.

A. Burke,A. Farb,R. Virmani

IF: 8.209

1991-03-01

Modern Pathology

Abstract:

What problem does this paper attempt to address?

Occurrence of a Thiothrix sp. Attached to Mayfly Larvae and Presence of Parasitic Bacteria in the Thiothrix sp

J. Larkin,M. Henk,S. D. Burton

DOI: https://doi.org/10.1128/aem.56.2.357-361.1990

1990-02-01

Applied and Environmental Microbiology

Abstract:Larvae of the mayfly (Drunella grandis [Eaton]) from Diamond Fork Creek, Utah, were covered with a heavy growth of the sulfide-oxidizing bacterium Thiothrix. The bacterium did not seem to harm the mayfly, but the Thiothrix trichomes were parasitized by three morphologically distinct bacteria, two of which were cytoplasmic and one of which was probably periplasmic. At least two of the parasites destroyed the cytoplasmic contents of the Thiothrix sp., thus killing the host cell. Attempts to obtain the parasites in pure culture were unsuccessful.
Neurological Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors

Sotiria Stavropoulou De Lorenzo,Athina Andravizou,Harry Alexopoulos,Iliana Michailidou,Alexandros Bokas,Evangelia Kesidou,Marina-Kleopatra Boziki,Dimitrios Parissis,Christos Bakirtzis,Nikolaos Grigoriadis

DOI: https://doi.org/10.3390/biomedicines12061319

IF: 4.757

2024-06-14

Biomedicines

Abstract:The use of immune checkpoint inhibitors (ICIs) for the treatment of various advanced and aggressive types of malignancy has significantly increased both survival and long-term remission rates. ICIs block crucial inhibitory pathways of the immune system, in order to trigger an aggravated immune response against the tumor. However, this enhanced immune activation leads to the development of numerous immune-related adverse events (irAEs), which may affect any system. Although severe neurological irAEs are relatively rare, they carry a high disability burden, and they can be potentially life-threatening. Therefore, clinicians must be alert and act promptly when individuals receiving ICIs present with new-onset neurological symptoms. In this narrative review, we have collected all the currently available data regarding the epidemiology, pathogenesis, clinical manifestations, diagnosis, and treatment of post-ICI neurological irAEs. This review aims to raise physicians' awareness, enrich their knowledge regarding disease pathogenesis, and guide them through the diagnosis and management of post-ICI neurological irAEs.

biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy
Medicinal flowers. VI. Absolute stereostructures of two new flavanone glycosides and a phenylbutanoid glycoside from the flowers of Chrysanthemum indicum L.: their inhibitory activities for rat lens aldose reductase.

H. Matsuda,T. Morikawa,I. Toguchida,S. Harima,M. Yoshikawa

DOI: https://doi.org/10.1248/CPB.50.972

2002-07-01

Chemical and Pharmaceutical Bulletin

Abstract:Two new flavanone glycosides, (2S)- and (2R)-eriodictyol 7-O-beta-D-glucopyranosiduronic acids, and a new phenylbutanoid glycoside, (2S, 3S)-1-phenyl-2,3-butanediol 3-O-beta-D-glucopyranoside, were isolated from the flowers of Chrysanthemum indicum L. cultivated in China together with eight flavonoids. The absolute stereostructures of the new compounds were determined on the basis of chemical and physicochemical evidence. Both of the new flavanone glycosides were found to show inhibitory activity for rat lens aldose reductase.
Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee.

Kuo-Hom Lee Hsu,M. Lubeck,Alan R. Davis,Ramesh A. Bhat,Bernard H. Selling,B. Bhat,Satoshi Mizutani,Brian R. Murphy,Peter L. Collins,R. M. Chanock,Paul P. Hung

DOI: https://doi.org/10.1093/INFDIS/166.4.769

1992-10-01

Abstract:Recombinant adenovirus type 4, 5, and 7 expressing the fusion glycoprotein (F) gene, the attachment glycoprotein (G) gene, or both F and G genes of respiratory syncytial virus (RSV) was constructed. Intratracheal immunization of dogs with Ad7F induced moderate titers of RSV-neutralizing antibodies. After booster immunization with Ad4F, the dogs developed high titers of RSV-specific antibody. Subsequently, three two-dose vaccination regimens, Ad4F/Ad5F, Ad7G/Ad4G, and Ad7FG/Ad4FG, were compared with Ad7F/Ad4F for immunogenicity and protective efficacy. The results indicated that Ad4F/Ad5F was equal or greater in immunogenicity to Ad7F/Ad4F, but Ad7G/Ad4G and Ad7FG/Ad4FG were less effective than Ad7F/Ad4F in inducing RSV-neutralizing antibody. All vaccination regimens completely protected the lungs of dogs from RSV infection. A chimpanzee was sequentially immunized orally with Ad7F, Ad4F, and Ad5F. A low-level antibody response to RSV was induced after the primary immunization, but no significant increases were observed after booster immunizations.
Central nervous system adverse events of immune checkpoint inhibitors

Antonio Farina,Macarena Villagrán-García,Alberto Vogrig,Bastien Joubert

DOI: https://doi.org/10.1097/wco.0000000000001259

2024-03-15

Current Opinion in Neurology

Abstract:Purpose of review Immune checkpoint inhibitors (ICI) may trigger immune-related adverse events which rarely affect the central nervous system (CNS-irAEs). Over the past few years, cumulative data have led to the characterization of well defined syndromes with distinct cancer and antibody associations as well as different outcomes. Recent findings The most frequent CNS-irAE is encephalitis, which includes three main groups: meningoencephalitis, a nonfocal syndrome usually responsive to corticosteroids; limbic encephalitis, associated with high-risk paraneoplastic neurological syndromes (PNS) antibodies (e.g. anti-Hu, anti-Ma2) and neuroendocrine cancers, characterized by poor treatment response and outcomes; and cerebellar ataxia, with variable outcomes (worse when high-risk PNS antibodies are detected). Additionally, a diffuse encephalopathy without inflammatory findings, with poor response to corticosteroids and high mortality has been described. The spectrum of CNS-irAEs also includes meningitis, myelitis, and rarer presentations. A subset of CNS-irAEs (i.e. limbic encephalitis and/or rapidly progressive cerebellar ataxia) is undistinguishable from ICI-naïve PNS. Summary The clinical and outcomes diversity of CNS-irAEs suggests different pathogenic mechanisms, which need to be understood to establish more effective and specific treatment modalities. It is crucial to identify biomarkers able to predict which patients will experience severe CNS-irAEs, to anticipate their diagnosis, and to predict long-term outcomes.

neurosciences,clinical neurology
Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development

Ke Cheng,Yuqing Wang,Yuwen Zhou,Ruolan Xia,Liansha Tang,Jiyan Liu

DOI: https://doi.org/10.1177/11795549211056261

2021-01-01

Abstract:Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of multiple malignancies, especially in non-small cell lung cancer (NSCLC). With the extensive application of ICIs in clinical practice, clinicians have to manage their toxicities, which are often termed immune-related adverse events (irAEs). Several ICIs, such as nivolumab, pembrolizumab, atezolizumab, and durvalumab, have been approved by the US Food and Drug Administration (FDA) to treat advanced NSCLC, accompanied by a broad spectrum of toxicity reactions. However, ICIs-associated neurological toxicities, regarding polyneuropathy, Bell palsy, encephalopathy, and myasthenia gravis, as uncommon emerging toxicities have not been well recognized, present a challenge for clinicians to improve awareness of supervision, recognition, and management before death from them. Herein, we have summarized the incidence, diagnosis, clinical manifestations, potential mechanisms, treatments, and outcomes of ICIs-related neurotoxicity and optimized the management approach for NSCLC patients. Prompt recognition and proper management are indispensable to reduce the morbidity of these patients with immune-related neurological toxicities.
Immune checkpoint inhibitors and neurotoxicity: a focus on diagnosis and management for a multidisciplinary approach

Desirèe Speranza,Mariacarmela Santarpia,Francesco Luppino,Fausto Omero,Enrica Maiorana,Mariacarmela Cavaleri,Elena Sapuppo,Vincenzo Cianci,Alessia Pugliese,Vito Racanelli,Giulia Maria Camerino,Carmelo Rodolico,Nicola Silvestris

DOI: https://doi.org/10.1080/14740338.2024.2363471

2024-06-04

Expert Opinion on Drug Safety

Abstract:Introduction Although immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, the consequential over activation of the immune system is often complicated by adverse events that can affect several organs and systems, including the nervous system. The precise pathophysiology underlying neurological irAEs (n-irAEs) is not completely known. Around 3.8% of patients receiving anti‐CTLA‐4 agents, 6.1% of patients receiving anti‐PD‐1/PD-L1, and 12% of patients receiving combination therapies have n-irAEs. Most n-irAEs are low-grade, while severe toxicities have rarely been reported. in this article, we performed an updated literature search on immuno-related neurotoxicity on main medical research database, from February 2017 to December 2023.

pharmacology & pharmacy
Diagnosis and Differential Diagnosis of Neurological Adverse Events during Immune Checkpoint Inhibitor Therapy

Nora Möhn,Susann Mahjoub,Ralf Gutzmer,Imke Satzger,Gernot Beutel,Philipp Ivanyi,Heiko Golpon,Mike P Wattjes,Martin Stangel,Thomas Skripuletz

DOI: https://doi.org/10.1155/2020/8865054

2020-12-07

Abstract:Therapy with immune checkpoint inhibitors (ICIs) has improved overall survival and cancer-related morbidity of cancer treatment even in cancer entities with poor prognosis. Since the approval of the first ICI, ipilimumab, for treatment of advanced melanoma by the Food and Drug Administration (FDA) in 2011, the spectrum of indications and approved ICIs has grown, rapidly. Up to now, seven different ICIs for more than 20 indications are available. However, their mechanisms of action can lead to immune-related adverse events (irAEs). In particular, neurological irAEs are clinically relevant. Although they are rare, an early and accurate diagnosis is challenging and neurological disease course and sequelae are potentially fatal. Between 08/2017 and 03/2020, 31 patients received ICI treatment at Hannover Medical School and presented with neurological adverse events (N-irAEs). Treated malignancies were metastatic melanoma, bronchial carcinoma, and urothelial cell carcinoma. All patients received comprehensive neurological diagnostics including clinical examination and magnetic resonance imaging (MRI). Cerebrospinal fluid (CSF) analysis was obtained in 21 patients and electroneurography was performed in 22 patients. Although N-irAEs were suspected in all 31 patients, 11 patients had other conditions leading to neurological symptoms including tumor metastases in seven patients and hemorrhagic or ischemic stroke in four patients. In the following, these patients are referred to as the differential diagnosis (DD) group. Patients with N-irAEs suffered from immune mediated neuropathy (9/20), myositis and/or myasthenic syndrome (6/20), or encephalitis/cerebellitis (5/20). Except for cell count, CSF results did not differ between the N-irAEs and the DD group. Symptoms related to N-irAEs are rather unspecific potentially mimicking other tumor-related symptoms such as metastases. Patients with malignancy are predominantly not treated by neurologists. Because of the complexity of neurological symptoms, detailed neurological investigations in specialized institutions are necessary in patients with new neurological symptoms and need to be critically discussed with treating oncologists.
Neurological Adverse Effects of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T-Cell Therapy

Farhan Khalid,Rajshree Gupta,Rajvi Gor,Dairya Gor,Vinit Singh,Hussam Eltoukhy

DOI: https://doi.org/10.14740/wjon1575

Abstract:Immune checkpoint inhibitors (ICPIs) and chimeric antigen receptor (CAR) T-cell constitute recently approved novel therapies targeted to treat a wide number of malignancies. Both the treatments modulate the immune system and can cause a number of immune-related adverse events (irAEs), including polyendocrinopathies, gastrointestinal and neurological complications. This literature review focuses on the neurological side effects of these therapies as these are uncommon and alter the course of the treatment. Neurological complications involve the peripheral and central nervous system, including polyneuropathy, myositis, myasthenia gravis, demyelinating polyradiculopathy, myelitis, and encephalitis. If early recognized, the neurological complications can be treated effectively with steroids to reduce the potential of short-term and long-term complications. Therefore, early identification and treatment of irAEs are needed to optimize the outcomes associated with ICPI and CAR T-cell therapies.
Why we must value bank nurses.

N. Lipley

DOI: https://doi.org/10.7748/nm.22.10.5.s1

2016-03-01

Nursing Management

Abstract:EDITORIAL ADVISORY BOARD Jane Brookes Ward manager (paediatric medical), Nottingham Children’s Hospital, Nottingham Geraldine Cunningham Associate director of culture change, Barts Health NHS, London Paul Edwards Head of practice development, Bupa UK Care Services, Leeds Naomi Elliott Director of international initiatives, school of nursing and midwifery, Trinity College Dublin Paul Labourne Assistant nurse director, Powys Teaching Health Board Anastasia Mallidou Assistant professor, school of nursing, University of Victoria BC, Canada Ada ter Maten Nurse researcher, Rotterdam University of Applied Sciences, Institute of Healthcare, Netherlands Niall McCrae Lecturer at the Florence Nightingale School of Nursing and Midwifery, King’s College London Jane Naish Associate director of nursing, Croydon Health Services NHS Trust, Surrey Natasha Phillips Assistant chief nurse, University College London Hospitals NHS Foundation Trust, and visiting research fellow, National Nursing Research Unit, King’s College London Elaine Strachan-Hall Clinical director of Healthcare at Home and registered nurse on South Warwickshire Clinical Commissioning Group’s governing body Helen Ward Associate professor in non-medical prescribing, London South Bank University Frances Wong Professor and associate dean, Hong Kong Polytechnic University, Hong Kong, China Haiou Xia Professor at the school of nursing, Fudan University, China
Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related adverse reactions in the nervous system

Jiayu Shi,Jingwen Niu,Dongchao Shen,Mingsheng Liu,Ying Tan,Yi Li,Yangyu huang,Liying Cui,Yuzhou Guan,Li Zhang

DOI: https://doi.org/10.1111/1759-7714.13266

IF: 3.223

2019-12-10

Thoracic Cancer

Abstract:Immune checkpoint inhibitors (ICIs) can cause adverse reactions in the nervous system. The incidence rate is 0.1%–12% and 80% of nervous system adverse reactions occur within the first four months of application. ICIs can cause diseases of various parts of the nervous system including central nervous system diseases such as aseptic meningitis, meningeal encephalitis, necrotizing encephalitis, brainstem encephalitis, transverse myelitis, etc., and peripheral neuropathy such as cranial nerve peripheral neuropathy, multifocal nerve root neuropathy, Guillain‐Barré syndrome, spinal nerve root neuropathy, myasthenia gravis, myopathy, etc. For these complications of the nervous system, diagnosis could be difficult. Physicians require a specific collection of nervous system symptoms and signs, combined with supplementary examinations including imaging, cerebrospinal fluid cytology, EEG or electromyography in order to exclude infection or malignant tumor before reaching a final diagnosis. With regard to treatment, ICIs should be discontinued in severe cases, and large doses of glucocorticoid or gamma globulin administered, and supportive treatment may be necessary. If severe adverse reactions of the nervous system occur, the prognosis could be poor.

oncology,respiratory system
Mannoside storage and axonal dystrophy in sensory neurones of swainsonine-treated rats: Morphogenesis of lesions

C. Huxtable,P. Dorling

DOI: https://doi.org/10.1007/BF00688958

IF: 15.887

Acta Neuropathologica

Abstract:
Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice

M. Villagrán-García,R. Velasco

DOI: https://doi.org/10.1007/s10072-022-05920-4

2022-02-17

Neurological Sciences

Abstract:Neurological, immune-related adverse events (n-irAE) due to immune checkpoint inhibitors (ICI) represent a growing clinical problem in neuro-oncology practice. Although rare, the frequency of n-irAEs will increase as ICI use becomes more common. Central and peripheral nervous systems may be involved, and multiple n-irAEs like myositis, myasthenia gravis, and myocarditis can arise in the same patient. Prompt recognition, initial ICI discontinuation, and treatment with immunosuppressive therapy comprise key aspects of managing these potentially fatal neurological complications. Severe and/or treatment-refractory n-irAEs may occur and require individualized care. In the same vein, a possible reintroduction of ICI after a n-irAE represents an additional challenge in clinical practice. An approach by experienced neurologists involved in highly subspecialized, multidisciplinary care teams is, therefore, of major importance in managing these cases. The present study updates current knowledge regarding presentation forms, diagnostic workflows, outcomes, and general management of n-irAEs. With the aim to guide neurologists in decision-making processes during such scenarios, the study further reviews available data on ICI reintroduction safety in patients with prior n-irAEs.

neurosciences,clinical neurology
Denervation reduces extractable met-enkephalin-like immunoreactivity in guinea-pig lips

G. Feurle,W. Hartschuh,U. Weber

DOI: https://doi.org/10.1016/0304-3940(83)90230-6

IF: 3.197

1983-10-31

Neuroscience Letters

Abstract:
Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors

Sophie L. Duong,Harald Prüss

DOI: https://doi.org/10.1007/s13311-022-01184-0

IF: 6.088

2022-01-18

Neurotherapeutics

Abstract:Abstract The introduction of immune checkpoint inhibitors (ICIs) in oncologic therapies has led to a paradigm shift in cancer treatment. ICIs have increased the overall survival in patients with malignant melanoma, small-cell lung cancer, and many other tumor entities. Despite their clinical benefits, these novel cancer immunotherapies can induce neurological immune-related adverse events (irAEs). Such immune-mediated complications can manifest within the spectrum of paraneoplastic neurological syndromes (PNSs). PNSs are rare immune-mediated complications of systemic cancers that can involve every aspect of the nervous system. The emergence of PNSs with ICI treatment opens further pathways to study the complex immunopathological interplay of cancer immunity, cross-reactive neurological autoimmune phenomena, and effects of ICIs on the immune system. ICI-induced PNSs comprise a diverse antibody repertoire and phenotypic spectrum with severe and life-threatening disease progression in some cases. Timely diagnosis and urgent interventions are pivotal for a favorable neurologic and oncologic outcome. This review focuses on the pathogenesis of cancer immunotherapy and the disruption of immune tolerance in PNSs and provides an overview of the most pertinent clinical manifestations and principles of diagnostic and therapeutic managements in light of the expected increase in PNSs due to the widespread use of ICIs in clinical practice. This review further discusses potential and evolving concepts of therapeutic monoclonal antibodies for the treatment of PNSs.

pharmacology & pharmacy,neurosciences,clinical neurology
Peripheral nervous system adverse events associated with immune checkpoint inhibitors

Simone Rossi,Francesco Gelsomino,Rita Rinaldi,Lorenzo Muccioli,Francesca Comito,Alessandro Di Federico,Andrea De Giglio,Giuseppe Lamberti,Elisa Andrini,Veronica Mollica,Roberto D’Angelo,Flavia Baccari,Corrado Zenesini,Pierandrea Madia,Emanuel Raschi,Pietro Cortelli,Andrea Ardizzoni,Maria Guarino

DOI: https://doi.org/10.1007/s00415-023-11625-1

2023-02-19

Journal of Neurology

Abstract:Background Immune checkpoint inhibitors (ICIs) represent an effective cancer immunotherapy yet are associated with immune-related adverse events (irAEs). The aim of this study was to characterize irAEs involving the peripheral nervous system (PNS-irAEs) in a real-world cohort of ICI-treated patients. Methods Cancer patients treated with ICIs between January 2014 and March 2022 were included. Patients with PNS-irAEs were identified and divided into two groups: (1) cranial/peripheral neuropathies and (2) myasthenia gravis (MG) and/or myositis. Clinical characteristics and outcomes, measured with the modified Rankin Scale (mRS), were compared among the two groups. Results Among 920 ICI-treated patients, 20 patients (2.17%) developed a PNS-irAEs. The median latency from ICI exposure was 8.8 weeks and the median time from onset to clinical nadir was 3.5 weeks. Eleven patients developed a neuropathy: polyneuropathy ( n = 4), cranial neuropathy ( n = 3), small-fiber neuropathy ( n = 3), brachial plexopathy ( n = 1). Nine patients presented MG and/or myositis: concomitant MG and myositis ( n = 6), isolated myositis ( n = 2), exacerbation of MG ( n = 1). Immunosuppressive treatment and/or ICI withdrawal determined a significant clinical improvement, expressed by a mRS reduction, in the neuropathy group ( p = 0.004), but not in the MG/myositis group ( p = 0.11). Overall, death due to irAEs occurred in four patients (20%), all with MG/myositis. Compared to patients with neuropathies, those with MG/myositis had a shorter latency onset ( p = 0.036), developed more frequently concomitant non-neurologic irAEs ( p = 0.028) and showed a higher mortality rate ( p = 0.026). Conclusions In our large cohort of ICI-treated patients, 2.17% developed PNS-irAEs. Compared to ir-neuropathies, ir-MG/myositis tend to occur earlier from ICI exposure and present a worse response to treatment and a higher mortality.

clinical neurology
Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy

Claire Perrinjaquet,Nicolas Desbaillets,Andreas F Hottinger

DOI: https://doi.org/10.1097/WCO.0000000000000686

Abstract:Purpose of review: Immune checkpoint inhibitors (ICPI) and chimeric antigen receptor T cells (CAR-T) represent novel therapies recently approved to treat a number of human cancers. As both approaches modulate the immune system, they can generate a number of immune-related adverse events (irAEs), including a large spectrum of novel neurological toxicities. These are of special interest given their potential severity and risk of compromising further oncologic treatment. We aim to provide a comprehensive review of the literature and discuss their optimal management. Recent findings: In contrast to irAEs involving other organs, neurological complications of ICPI are uncommon, may present throughout the course of treatment and involve the peripheral and central nervous system, including polyneuropathy, myositis, myasthenia gravis, demyelinating polyradiculopathy, myelitis, encephalitis and others. If started early, ICPI-related neurologic irAEs are usually responsive to steroids. In contrast, as many as 40% of patients undergoing CAR-T therapy will develop neurologic complications in the form of a cytokine-release-associated encephalopathy. It includes delirium, aphasia, tremor/myoclonus, seizure and seizure-like activity. Summary: irAEs associated with CAR-T and ICPI therapy constitute new entities. Early identification and treatment are essential to optimize the functional outcome and further oncologic management of the patient.
Achilles' Heel of currently approved immune checkpoint inhibitors: immune related adverse events

Ting Yan,Lun Yu,Jiwen Zhang,Yun Chen,Yilan Fu,Jingyi Tang,Dehua Liao

DOI: https://doi.org/10.3389/fimmu.2024.1292122

IF: 7.3

2024-02-12

Frontiers in Immunology

Abstract:Immunotherapy has revolutionized the cancer treatment landscape by opening up novel avenues for intervention. As the use of immune checkpoint inhibitors (ICIs) has exponentially increased, so have immune-related adverse events (irAEs). The mechanism of irAEs may involve the direct damage caused by monoclonal antibodies and a sequence of immune responses triggered by T cell activation. Common side effects include dermatologic toxicity, endocrine toxicity, gastrointestinal toxicity, and hepatic toxicity. While relatively rare, neurotoxicity, cardiotoxicity, and pulmonary toxicity can be fatal. These toxicities pose a clinical dilemma regarding treatment discontinuation since they can result in severe complications and necessitate frequent hospitalization. Vigilant monitoring of irAEs is vital in clinical practice, and the principal therapeutic strategy entails the administration of oral or intravenous glucocorticoids (GSCs). It may be necessary to temporarily or permanently discontinue the use of ICIs in severe cases. Given that irAEs can impact multiple organs and require diverse treatment approaches, the involvement of a multidisciplinary team of experts is imperative. This review aims to comprehensively examine the pathogenesis, clinical manifestations, incidence, and treatment options for various irAEs.

immunology
Cutaneous metastasis from gastric glomus tumour

A. Bray,N. Wong,S. Narayan

DOI: https://doi.org/10.1111/j.1365-2230.2009.03445.x

2009-12-01

Abstract:A 58‐year‐old man presented with a 4‐month history of a rapidly enlarging asymptomatic tumour on the scalp vertex. Six years earlier, the patient had undergone subtotal gastrectomy for a presumed gastrointestinal stromal tumour (GIST). The tumour extended to the peritoneal surfaces, and foci of vascular invasion were also seen. No adjuvant treatment was given. Owing to diagnostic difficulties with the scalp tumour, a comparison was made with the previous gastric neoplasm. Both had features consistent with glomus tumour, which suggested a revised diagnosis of primary malignant gastric glomus tumour with subsequent cutaneous metastasis to the scalp some years later. This case highlights the features of glomus tumours and is a reminder that although rare, glomus tumours can be malignant and have the potential to metastasize. To our knowledge, this is the only reported case of a primary gastric glomus tumour with secondary metastasis to the skin.
Quality Assessment of Meta-analyses Published in Leading Anesthesiology Journals From 2005 to 2014

A. Hall,Sandra Lee,D. Zurakowski

DOI: https://doi.org/10.1213/ANE.0000000000002074

2017-06-01

Abstract:Meta-analysis, when preceded by a systematic review, is considered the “gold standard” in data aggregation; however, the quality of meta-analyses is often questionable, leading to uncertainty about the accuracy of results. In this study, we evaluate the quality of meta-analyses published in 5 leading anesthesiology journals from 2005 to 2014. A total of 220 meta-analyses published in Anesthesiology, Pain, British Journal of Anaesthesia, Anaesthesia, or Anesthesia & Analgesia were identified for inclusion. The quality of each meta-analysis was determined using the Revised Assessment of Multiple Systematic Reviews (R-AMSTAR). R-AMSTAR rated 11 questions related to systematic reviews and meta-analyses on a scale of 1–4, with 4 representing the highest quality. Overall meta-analyses quality was evaluated using a Spearmen regression analysis and found to positively correlate with time (rs = 0.24, P < .001). Similarly, a temporal association was found for conflict of interest (rs = 0.51, P < .001) and comprised a list of included and excluded studies (rs = 0.32, P < .001). In conclusion, the quality of meta-analyses published in leading anesthesiology journals has increased over the last decade. Furthermore, assessing the scientific quality of included studies in meta-analyses (P = .60) and using this assessment to formulate conclusions and/or recommendations (P = .67) remains relatively low (median R-AMSTAR: 2, interquartile range [IQR]: 2–3]; median R-AMSTAR: 2, IQR: 1–2, respectively).

The pathology of primary pulmonary hypertension.

Occurrence of a Thiothrix sp. Attached to Mayfly Larvae and Presence of Parasitic Bacteria in the Thiothrix sp

Neurological Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors

Medicinal flowers. VI. Absolute stereostructures of two new flavanone glycosides and a phenylbutanoid glycoside from the flowers of Chrysanthemum indicum L.: their inhibitory activities for rat lens aldose reductase.

Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee.

Central nervous system adverse events of immune checkpoint inhibitors

Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development

Immune checkpoint inhibitors and neurotoxicity: a focus on diagnosis and management for a multidisciplinary approach

Diagnosis and Differential Diagnosis of Neurological Adverse Events during Immune Checkpoint Inhibitor Therapy

Neurological Adverse Effects of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T-Cell Therapy

Why we must value bank nurses.

Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related adverse reactions in the nervous system

Mannoside storage and axonal dystrophy in sensory neurones of swainsonine-treated rats: Morphogenesis of lesions

Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice

Denervation reduces extractable met-enkephalin-like immunoreactivity in guinea-pig lips

Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors

Peripheral nervous system adverse events associated with immune checkpoint inhibitors

Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy

Achilles' Heel of currently approved immune checkpoint inhibitors: immune related adverse events

Cutaneous metastasis from gastric glomus tumour

Quality Assessment of Meta-analyses Published in Leading Anesthesiology Journals From 2005 to 2014